| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenues: | ||||||
Total revenues | ||||||
1,169 | 1,464 | 4,026 | - | - | - | |
Operating expenses (income): | ||||||
Product | ||||||
- | - | - | 669 | 466 | 355 | |
License | ||||||
- | - | - | 144 | 1,216 | 2,325 | |
Contract research and government grants | ||||||
- | - | - | 2,375 | 3,732 | 4,302 | |
Total revenues | ||||||
- | - | - | 3,188 | 5,414 | 6,982 | |
Operating expenses: | ||||||
Cost of product revenues | ||||||
- | - | - | 895 | 892 | 1,997 | |
Research and development | ||||||
7,098 | 6,069 | 7,407 | 8,663 | 8,966 | 10,012 | |
Change in fair value of contingent consideration | ||||||
-1,000 | - | - | - | - | - | |
Selling, general and administrative | ||||||
13,567 | 11,604 | 10,651 | 12,250 | 11,119 | 10,126 | |
Total operating expenses | ||||||
20,550 | 18,334 | 18,341 | 21,808 | 20,977 | 22,135 | |
Loss from operations | ||||||
-19,381 | -16,870 | -14,315 | -18,620 | -15,563 | -15,153 | |
Interest expense | ||||||
5 | - | 747 | 1,319 | 2,658 | 1,394 | |
Other income, net | ||||||
466 | 394 | 281 | 340 | 521 | -597 | |
Initial loss on common stock warrant and common stock adjustment feature liabilities | ||||||
- | 4,000 | - | - | - | - | |
Change in fair value of common stock warrant liabilities | ||||||
9,243 | -9,561 | - | - | - | - | |
Offering costs | ||||||
708 | 2,555 | - | - | - | - | |
Loss on extinguishment of debt | ||||||
- | - | -900 | - | -230 | 0 | |
Net income (loss) before income taxes | ||||||
-28,871 | -13,470 | -15,681 | - | - | - | |
Net loss before income taxes | ||||||
- | - | - | -19,599 | -17,930 | - | |
Net loss before income taxes and equity in loss of unconsolidated entity | ||||||
- | - | - | - | - | -17,144 | |
Income tax provision | ||||||
2 | 10 | 26 | 25 | 26 | 263 | |
Net income (loss) | ||||||
-28,873 | -13,480 | - | - | - | - | |
Net loss attributable to non-controlling interest | ||||||
-68 | - | - | - | - | - | |
Equity in loss of unconsolidated entity | ||||||
- | - | - | - | - | -932 | |
Net income (loss) attributable to common stockholders | ||||||
-28,805 | -13,480 | -15,707 | -19,624 | -17,956 | -18,339 | |
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | - | - | 2,574 | 3,738 | |
Deemed dividends to warrant holder | ||||||
- | - | - | - | 197 | 0 | |
Net loss attributable to common stockholders | ||||||
- | - | - | - | -20,727 | -22,077 | |
Net income (loss) per share attributable to common stockholders: | ||||||
Basic and diluted | ||||||
-4.53 | -3.58 | -7.28 | -8.85 | -0.73 | -10.71 | |
Weighted-average number of shares used in per share calculations: | ||||||
Basic and diluted | ||||||
6,363 | 3,766 | 2,156 | 2,218 | 28,559 | 2,061 | |
Other comprehensive loss, net of tax | ||||||
Unrealized losses on available-for-sale securities | ||||||
1 | - | 18 | 96 | -115 | 0 | |
Other comprehensive loss | ||||||
1 | - | 18 | 96 | -115 | 0 | |
Comprehensive income (loss) attributable to common stockholders | ||||||
-28,804 | -13,480 | -15,689 | -19,528 | -20,842 | -22,077 | |
Product | ||||||
Total revenues | ||||||
814 | 657 | 514 | - | - | - | |
Cost of product revenues | ||||||
885 | 661 | 283 | - | - | - | |
License | ||||||
Total revenues | ||||||
67 | 150 | 1,470 | - | - | - | |
Contract Research And Government Grants | ||||||
Total revenues | ||||||
288 | 657 | 2,042 | - | - | - | |